To attest the pre-clinical value of targeting the SMYD2-BCAR3 pathway to prevent breast cancer dissemination, we performed in vivo metastasis experiment with the selective SMYD2 catalytic inhibitor BAY-59835. Here, SMYD2 is linked to breast carcinoma.